seed
Stage
About
TippingPoint Biosciences develops novel therapeutics that target dysfunctional chromatin networks by drugging unstructured regions in chromatin proteins, aiming to treat diseases such as certain cancers with improved specificity and reduced toxicity.
Explore TippingPoint Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.